We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Membrane-Bound Enzyme Linked to Plaque Formation in Mouse Atherosclerosis Model

By LabMedica International staff writers
Posted on 21 Jul 2015
Cardiac disease researchers working with a mouse model of atherosclerosis have found that that a specific membrane bound enzyme has the potential to inhibit build-up of plaque and reduce risk of heart attack or stroke.

Investigators at the University of Michigan (Ann Arbor, USA) worked with the apolipoprotein E-deficient (ApoE-deficient) mouse model of atherosclerosis to examine the role of the enzyme CD39 (ectonucleotide tri(di)phosphohydrolase-1 or ENTPD1) in the process of plaque formation. More...
This enzyme metabolizes locally released, intravascular ATP and ADP, thereby eliminating these pro-thrombotic and pro-inflammatory signaling molecules.

The investigators reported in the June 29, 2015, online edition of the Journal of Clinical Investigation that when animals fed a high-fat diet were compared, it was seen that ApoE-deficient mice that also lacked CD39 had a plaque burden that was markedly increased along with circulating markers of platelet activation. CD39 was prominently expressed in stable blood flow regions and was diminished in areas subjected to disturbed flow. Thus, CD39 activation followed the pattern of plaque formation.

In mice, disturbed blood flow as the result of partial carotid artery ligation rapidly suppressed endothelial CD39 expression. Moreover, unidirectional laminar shear stress induced protective CD39 expression in human endothelial cells.

“Better lifestyles and improved treatments have slowed the rates of death from atherosclerosis, but if CD39 proves to be as critical a factor in humans as in mice, it would be a major step forward in understanding heart disease,” said senior author Dr. David Pinsky, professor of cardiology at the University of Michigan.

Related Links:

University of Michigan



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.